Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C A Seipp

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Cancer Treatment Reports|May 1, 1979
Treatment of osteogenic sarcoma. I. Effect of adjuvant high-dose methotrexate after amputationS A Rosenburg, B A Chabner, R C Young, et al.
Cancer|July 1, 1986
High-grade soft tissue sarcomas of the extremitiesD A Potter, T Kinsella, E Glatstein, et al.
JAMA|March 23, 1994
Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2S A Rosenberg, J C Yang, S L Topalian, et al.
Cancer|August 15, 1995
The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2J C Yang, S L Topalian, D J Schwartzentruber, et al.
The New England Journal of Medicine|December 22, 1988
Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary reportS A Rosenberg, B S Packard, P M Aebersold, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1988
Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot studyS L Topalian, D Solomon, F P Avis, et al.
Journal of the National Cancer Institute|April 21, 1993
Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancerS A Rosenberg, M T Lotze, J C Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 1999
Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2bS A Rosenberg, J C Yang, D J Schwartzentruber, et al.
Journal of the National Cancer Institute|August 3, 1994
Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2S A Rosenberg, J R Yannelli, J C Yang, et al.
Journal of the National Cancer Institute|December 23, 1998
Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigensS A Rosenberg, Y Zhai, J C Yang, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Cancer Treatment Reports|May 1, 1979
Treatment of osteogenic sarcoma. I. Effect of adjuvant high-dose methotrexate after amputationS A Rosenburg, B A Chabner, R C Young, et al.
Cancer|July 1, 1986
High-grade soft tissue sarcomas of the extremitiesD A Potter, T Kinsella, E Glatstein, et al.
JAMA|March 23, 1994
Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2S A Rosenberg, J C Yang, S L Topalian, et al.
Cancer|August 15, 1995
The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2J C Yang, S L Topalian, D J Schwartzentruber, et al.
The New England Journal of Medicine|December 22, 1988
Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary reportS A Rosenberg, B S Packard, P M Aebersold, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1988
Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot studyS L Topalian, D Solomon, F P Avis, et al.
Journal of the National Cancer Institute|April 21, 1993
Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancerS A Rosenberg, M T Lotze, J C Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 1999
Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2bS A Rosenberg, J C Yang, D J Schwartzentruber, et al.
Journal of the National Cancer Institute|August 3, 1994
Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2S A Rosenberg, J R Yannelli, J C Yang, et al.
Journal of the National Cancer Institute|December 23, 1998
Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigensS A Rosenberg, Y Zhai, J C Yang, et al.
Pageof 4